Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
Brian R BourbeauGary H LymanXiudong Jennifer LeiLee JonesJon RosenthalMary May Priscilla KozlikKurt R OettelAlfred TingerRay D PagePublished in: JCO oncology practice (2023)
Biosimilars have, through increased use, lowered the average cost per dose of the studied biologics. Biosimilar use differed by originator biologic, practice type, and payment source. There remains further opportunity for increases in biosimilar use among certain practices and payers.